Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 3/20 | 0.46 |
| ▸ | NOS3 | P29474 | 2/20 | 0.45 |
| ▸ | NOS1 | P29475 | 2/20 | 0.45 |
| ▸ | NOS2 | P35228 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 4/20 | 0.43 |
| ▸ | CDC7 | O00311 | 3/20 | 0.42 |
| ▸ | DBF4 | Q9UBU7 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | BPTF | Q12830 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | EEF2K | O00418 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | PI4KA | P42356 | 1/20 | 0.36 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.36 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL361602 | 0.95 | LIMK1 (0.46) | LIMK1NOS3NOS1NOS2ACHE | |
| SCHEMBL30095833 | 0.95 | LIMK1 (0.46) | LIMK1NOS3NOS1NOS2ACHE | |
| SCHEMBL4195565 | 0.77 | DYRK1A (0.35) | LIMK1DYRK1API4KAPI4K2BPI4K2A | |
| SCHEMBL31065827 | 0.77 | PNMT (0.34) | LIMK1NOS3NOS1NOS2CDC7 | |
| Hydrochloric Acid SCHEMBL30170812 | 0.75 | DYRK1A (0.34) | LIMK1DYRK1API4KAPI4K2BPI4K2A | |
| SCHEMBL30666837 | 0.73 | TSHR (0.37) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL31326619 | 0.73 | TSHR (0.41) | LIMK1NOS3NOS1NOS2ACHE | |
| SCHEMBL9433900 | 0.73 | TSHR (0.37) | LIMK1NOS3NOS1NOS2ACHE | |
| SCHEMBL855087 | 0.73 | TSHR (0.37) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL16079383 | 0.73 | KDM4E (0.45) | NOS3NOS1NOS2ACHECDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110115365-A | The adjusting that actinism receptor and relative ligand are carried out | 西诺米克斯公司 | 2019-08-13 | — | — | CN | disclosed |
| US-10174005-B2 | Fused pyrimidines as inhibitors of p97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180044325-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES, INC. | 2018-02-15 | — | — | US | disclosed |
| CN-101779124-B | Modulation of chemosensory receptors and ligands associated therewith | 西诺米克斯公司 | 2017-12-12 | — | — | CN | disclosed |
| CN-107459508-A | Annelated pyrimidines as the inhibitor of P97 compounds | 克里弗生物科学公司 | 2017-12-12 | — | — | CN | disclosed |
| US-9828363-B2 | Fused pyrimidines as inhibitors of P97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| CN-107365319-A | The regulation carried out to actinism acceptor and relative part | 西诺米克斯公司 | 2017-11-21 | — | — | CN | disclosed |
| CN-104768946-B | Fused pyrimidines as inhibitors of the p97 complex | 克里弗生物科学公司 | 2017-05-03 | — | — | CN | disclosed |
| US-20160332990-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| CN-104768946-A | Fused pyrimidines as inhibitors of the p97 complex | CLEAVE BIOSCIENCES INC | 2015-07-08 | — | — | CN | disclosed |
| CN-102548557-A | Compounds for reducing beta-amyloid production | BRISTOL MYERS SQUIBB CO | 2012-07-04 | — | — | CN | disclosed |
| WO-1994011365-A1 | SUBSTITUTED BENZIMIDAZOLES AND QUINAZOLINES AS ANTIHYPERTENSIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174005-B2 | Fused pyrimidines as inhibitors of p97 complex | WDR77, POP1, PSMG3 | LIMK1 3684/4885NOS3 4758/4885NOS1 4846/4885 |
| US-20160332990-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | WDR77, POP1, PSMG3 | LIMK1 3684/4885NOS3 4758/4885NOS1 4846/4885 |
| US-20180044325-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | WDR77, POP1, PSMG3 | LIMK1 3683/4885NOS3 4757/4885NOS1 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.